

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: Psyched Wellness Ltd. (“Psyched Wellness” or the “Company”)

Trading Symbol: PSYC

Number of Outstanding Listed Securities: 105,534,130 Common Shares

Date: December 31, 2020

Report on Business

1. Provide a general overview and discussion of the development of the Issuer’s business and operations over the previous month. Where the Issuer was inactive disclose this fact.

On December 2, 2020, Psyched Wellness announced that it has successfully up-listed its common shares from the OTC Pink Market to the OTCQB® Venture Market. The Company will continue to trade under the symbol “DCNPF” until such time a symbol change request is completed.

On December 7, 2020, the Company provided highlights on its toxicology assessments conducted to determine the safe use of an Amanita Muscaria extract and the active compounds that comprise the extract. For key findings from the toxicology assessment, please refer to the press release dated December 7, 2020 posted under the Company’s SEDAR profile at www.sedar.com.

On December 8, 2020, the Company announced that Aaron Slater has joined its advisory board to work with the team on exploring new markets for its products and identifying possible M&A opportunities.

On December 10, 2020, the Company announced that it had completed a comprehensive process of lab experiments which have determined the Company’s final extraction protocol which will be used for its first line of products. The Company also announced that it has completed the assembly of the safety and efficacy narratives, and the writing of the safety data sheets for its unique Amanita Muscaria extract.

On December 15, 2020, the Company announced that it had completed its first extraction of a legal psychedelic derived from Amanita Muscaria mushrooms.

On December 23, 2020, the Company announced that it had shipped its first batch of Amanita Muscaria extract to its CRO partner to commence the Pre-Clinical trials. The Company sent 108 grams of highly concentrated Amanita

Muscaria extract to its CRO's lab to begin the first phase of its Pre-Clinical Trial. This first batch of Amanita extract will be used in a study to determine the Maximum Tolerated Dose. The goal of the study is to determine the highest dose of our extract that will not cause unacceptable side effects or an overt toxicity in a defined period. This is a key first step in determining the appropriate dosage for our future products.

On December 29, 2020, the Company announced that it had commenced research on Muscimol for various ailments, with a focus on mental health issues. The research is led by the Company's board member, Prof. David Nutt. The purpose of the research is to gather all the scientific papers surrounding Muscimol and its various ailments, in order to support using Muscimol for mental health issues.

2. Provide a general overview and discussion of the activities of management.

Having now obtained a listing on the Canadian Securities Exchange, management continues to work with its advisors and CRO partners on research and development ("R&D") and formulation of its flagship product, an *Amanita Muscaria* mushroom-infused tincture. The Company completed toxicology assessments, including safety margins analysis for human consumption, complete a gap analysis and path to market assessment, R&D on extraction methods, determine the applicable regulatory and labeling requirements, complete branding artwork and package design. The Company, through its CRO partners, has commenced a pre-clinical study including rodent testing to ensure the safety and efficacy of the product and to identify safe dosage levels. In addition, it has commenced a shelf life study to establish the durable life our product. A relationship with a Canadian-based distributor has been established, which will position the Company to get its products in Canadian retail locations. In addition to selling products in retail locations, management will build an e-commerce marketplace and evaluate various web fulfillment and logistics companies for distribution from the marketplace in the Canadian and United States markets.

With the official commencement of our pre-clinical trials to determine the safety, efficacy, and safe dosage levels for Amanita Muscaria, this is the foundation off which the Company can apply to the FDA for a New Dietary Ingredient (NDI) and Health Canada for a Natural Health Product Number (NHPN) for our Amanita Muscaria supplement. It will also provide the IP required to focus our team's attention on studying other more clinical uses of Amanita Muscaria for mental and physical health issues."

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

There were no new products or services developed or offered during the month.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

There were no products or services which were discontinued during the month.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

Aside from business relationships entered into in the normal course of business from time to time during the last month, the Company has no further new business relationships to report.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

There were no material contracts or agreements expired or terminated during the month and no other material financing arrangements were cancelled during the month.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

There were no acquisitions or dispositions of assets made during the month.

8. Describe the acquisition of new customers or loss of customers.

None noted.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trademarks.

None noted.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

Aside from the hiring or termination of employees in the normal course of business, the Issuer had no further hirings or terminations to report.

11. Report on any labour disputes and resolutions of those disputes if applicable.

None noted.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

There are currently no legal proceedings against the Company.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

None noted.

14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds ⁽¹⁾
Common shares	1,021,200	Exercise of broker warrants	\$102,120
Options	250,000	Grant of options to an advisory board member	N/A

15. Provide details of any loans to or by Related Persons.

None noted.

16. Provide details of any changes in directors, officers or committee members.

None noted.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

The trends and risks which are likely to impact Psyched Wellness' business and operations are detailed in the Company's Listing Statement dated October 21, 2020, under the heading "Risk Factors"; in the Company's most recently filed Management's Discussion and Analysis; and in the Company's other public filings, all of which are available under the Company's SEDAR profile at www.sedar.com, and which are incorporated into this report by reference thereto.

In addition, on January 30, 2020, the World Health Organization declared that the recent COVID-19 outbreak was a global health emergency, recognizing that the disease represents a risk outside of China, where it emerged in the last several months. Companies across various industries could be impacted materially by the coronavirus.

COVID-19's known and unknown impact on earnings, costs, employees, supply chains, customers and other stakeholders, as well as other business matters, may be material for the Company, and may have a material impact on the Company's future earnings, and other business matters. Environmental, social and governance factors may also impact the Company' operations in the near future.

Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: January 4, 2021.

Jeffrey Stevens
Name of Director or Senior Officer

"Jeffrey Stevens"
Signature

Chief Executive Officer
Official Capacity

Issuer Details Name of Issuer Psyched Wellness Ltd.	For Month End December 31, 2020	Date of Report 21/01/04
Issuer Address 77 King Street West, Suite 3000		
City/Province/Postal Code Toronto, Ontario, M5K 1G8	Issuer Fax No. ()	Issuer Telephone No. (647) 400-8494
Contact Name Keith Li	Contact Position CFO	Contact Telephone No. (647) 660-8703
Contact Email Address kli@bransonservices.com	Web Site Address www.psyched-wellness.com	